Leiden, January 5th, 2022: SeraNovo and Graviton deepen collaboration and enter into a second license agreement to develop formulations for Graviton's ROCK-2 inhibitors
SeraNovo is pleased to announce the closing of a second license agreement with Graviton Bioscience Corporation (Graviton), a biopharmaceutical company engaged in the research and development of small molecules in the fields of oncology and neuroscience. Under the agreement, SeraNovo will license its deep eutectic solvent technology for the formulation of Graviton’s ROCK-2 inhibitors.
Niall Hodgins, SeraNovo’s Chief Executive Officer commented: “We are delighted to enter into this second license agreement with Graviton. We already have one joint program that will go into the clinic in the near future, and we are now broadening the scope of our collaboration to cover all of Graviton’s ROCK-2 inhibitors. This collaboration provides robust evidence of efficacy for our formulation platform”.
About SeraNovo: SeraNovo is an innovative formulation company improving the oral bioavailability of active pharmaceutical ingredients. The focus of the company is on solving the problem of poor drug solubility by designing tailor-made, deep eutectic solvent based formulations to increase oral bioavailability. SeraNovo is a privately owned company located in Leiden, the Netherlands and as technology inventor owns all know-how and IP. For more information, please visit www.seranovo.com.
About Graviton: Graviton Bioscience Corporation is a biopharmaceutical company focused on the discovery and development of small molecule drugs to treat serious unmet medical needs in oncology and neurological diseases. For more information, please visit www.graviton.bio
Forward-Looking Statements: This press release contains forward-looking statements, including but not limited to statements regarding development plans, the DES Formulation Platform, and product candidates and related capabilities. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from current expectations and projections. The parties expressly disclaim any intent or obligation to update these forward-looking statements except as required by law.
For further information, please contact us at firstname.lastname@example.org